The VHL Alliance
The VHL Alliance is dedicated to RESEARCH, EDUCATION, and SUPPORT to improve awareness, diagnosis, treatment, and quality of life for those affected by VHL.
Our vision is Curing Cancer through VHL
The VHL gene is in all of us, helping to suppress the growth of tumors. Those with a flaw in this gene are prone to develop tumors throughout their bodies. Researchers are racing to identify and control the pathways that allow tumor growth in VHL and other cancers. Their progress provides hope for all of us by Curing Cancer through VHL. Founded in 1993, the VHL Alliance (VHLA) is the world’s leading organization supporting von Hippel-Lindau Syndrome. We are a 501(c)3 nonprofit dedicated to improving the lives and optimizing the treatment of those affected VHL while aggressively pursuing a cure.
Condition Awareness & Advocacy
Here is a list of conditions this partner raises awareness and advocacy for:
Connect With the VHL Alliance
Patient Worthy Posts on VHL
Merck has just received FDA approval for their recently acquired drug Welireg. This HIF-2α blocker is indicated for von Hippel-Lindau disease (VHL). This rare disease
According to Ryan McDonald of Cure Today, the FDA recently granted Breakthrough Therapy Designation to MK-6482, an investigational HIF-2α inhibitor developed by Merck. The
Continued From Part Two Written by Payel Bhattacharya I hope for aid from the government to cover the high cost of subsequent medicines including
Continued From Part One written by Payel Bhattacharya Pharmaceutical science has medications to control the pain. I was initially put on medicine but it mostly
By Payel Bhattacharya, living with von Hippel-Lindau syndrome I, Miss Payel Bhattacharya, was an unusual child. I was never concerned with petty things, the trivia,
According to a story from Kractivist, 38 year old Payel Bhattacharya has the rare genetic disorder von Hippel-Lindau disease, or VHL. Payel has written a